21:41 , Jul 25, 2019 |  BC Innovations  |  Emerging Company Profile

Axial: targeting gut microbe metabolites for CNS disorders

Microbiome play Axial is using small molecules to treat the gut end of the gut-brain axis for Parkinson's disease and autism. Co-founder and CEO David Donabedian told BioCentury that Axial Biotherapeutics Inc. believes that the...
20:08 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...
13:00 , Feb 27, 2019 |  BC Extra  |  Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...